TCR2 Therapeutics (TCRR) Collaborates with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo and Yervoy in Mesothelin-Expressing Solid Tumors
Go back to TCR2 Therapeutics (TCRR) Collaborates with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo and Yervoy in Mesothelin-Expressing Solid Tumors| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 62.84 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $62.84 | 52 Week High | $77.12 | |||
| Open | $62.84 | 52 Week Low | $49.03 | |||
| Day High | $62.84 | P/E | 40.81 | |||
| Day Low | $62.84 | EPS | $1.54 | |||
| Volume | 13,577 | |||||
| (NASDAQ: TCRR) | Delayed: 1.48 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.48 | 52 Week High | $ | |||
| Open | $3.63 | 52 Week Low | $ | |||
| Day High | $1.48 | P/E | N/A | |||
| Day Low | $1.48 | EPS | $ | |||
| Volume | 52,452 | |||||
